Industry news that matters to you.  Learn more

Rosetta Genomics Receives Key U.S. Patent Allowance for its Cancer of Origin Diagnostic Assay

Reading time: 2 minutes

Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based assays, FISH testing and other molecular diagnostics, announces receipt of a Notice of Allowance for U.S. Patent Application No. 13/856,190, entitled, “Methods and materials for classification of tissue of origin of tumor samples.”

The allowed patent claims a method for identifying a tissue of origin of a cancer sample by the expression levels of 64 microRNAs using a combination of probes attached to a solid substrate, and employing a classifier algorithm in order to identify the tissue of origin. This patent specifically covers the second generation of Rosetta’s Cancer Origin Test™, which uses more markers and identifies a larger spectrum of cancers than the previous generation. Further, it is based on microarray technology for microRNA expression profiling.

“This U.S. patent allowance will provide core protection for one of our lead products, the Rosetta Cancer Origin Test™, which can accurately identify the primary tumor type in primary and metastatic cancer including cancer of unknown or uncertain primary. By accurately identifying the primary tumor origin, physicians are able to make more informed decisions, to select the best treatment choices and to optimize patient outcomes. This is particularly relevant with the number of new targeted oncology therapies coming to market,” said Kenneth A. Berlin, President and Chief Executive Officer of Rosetta Genomics. “Our growing intellectual property position continues to protect and solidify our global leadership position in microRNA biomarker technology while providing additional revenue generating opportunities for us and enhancing our leadership position in the commercialization of differentiated and/or proprietary content in the area of personalized medicine.”

Rosetta Genomics has 42 issued patents, five allowed patents and 45 patents pending worldwide.

Source: Business Wire